AFM
SPRO icon

Anson Funds Management’s Spero Therapeutics SPRO Stock Holding History

Anson Funds Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Buy
843,912
+218,850
+35% +$519K 0.09% 107
2025
Q4 		$1.46M Sell
625,062
-978,507
-61% -$2.27M 0.14% 80
2025
Q3 		$3.01M Sell
1,603,569
-11,900
-0.7% -$26.2K 0.27% 61
2025
Q2 		$4.68M Sell
1,615,469
-2,183,463
-57% -$3.14M 0.67% 30
2025
Q1 		$2.74M Sell
3,798,932
-40,954
-1% -$34.6K 0.5% 45
2024
Q4 		$3.96M Buy
3,839,886
+89,436
+2% +$106K 0.4% 40
2024
Q3 		$5.03M Hold
3,750,450
– – 0.5% 30
2024
Q2 		$4.88M Hold
3,750,450
– – 0.58% 25
2024
Q1 		$6.45M Sell
3,750,450
-547,249
-13% -$858K 0.42% 31
2023
Q4 		$6.32M Buy
4,297,699
+138,127
+3% +$165K 0.78% 29
2023
Q3 		$5.03M Buy
4,159,572
+714,710
+21% +$990K 1.01% 21
2023
Q2 		$5M Buy
3,444,862
+100,000
+3% +$171K 0.83% 24
2023
Q1 		$4.85M Buy
3,344,862
+325,254
+11% +$544K 0.79% 32
2022
Q4 		$5.22M Buy
3,019,608
+1,545,736
+105% +$2.89M 0.86% 29
2022
Q3 		$2.95M Buy
+1,473,872
New +$1.47M 0.35% 65

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Anson Funds Management's SPRO Position: Q1 2026 in Review

Anson Funds Management increased its Spero Therapeutics (SPRO) stake by 35% in Q1 2026, buying an estimated $519K and bringing the position to 843,912 shares worth $1.97M. The position accounts for 0.09% of the portfolio, ranked #107.

Anson Funds Management first reported a position in SPRO in Q3 2022 and has held it in 15 quarters since. The position peaked at $6.45M in Q1 2024. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Anson Funds Management held 843,912 shares of Spero Therapeutics worth $1.97M as of Q1 2026.
  • Anson Funds Management bought 218,850 Spero Therapeutics shares in Q1 2026, an estimated $519K.
  • Spero Therapeutics made up 0.09% of Anson Funds Management's portfolio in Q1 2026, its #107 holding.
  • Anson Funds Management first reported a position in Spero Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Anson Funds Management's Spero Therapeutics position peaked at $6.45M in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Anson Funds Management's 13F filing for Q1 2026, filed 14 May 2026.